MedPath

Effect of Intake of Allium Cepa L. Peel Heated Water Extract on Immunity Enhancement

Not Applicable
Active, not recruiting
Conditions
Upper Respiratory Infection
Interventions
Dietary Supplement: Placebo
Dietary Supplement: Allium Cepa L. Peel Heated Water Extract
Registration Number
NCT05666752
Lead Sponsor
Hanyang University
Brief Summary

This study was conducted to investigate the effects of daily supplementation of Allium Cepa L. Peel Heated Water Extract on Immunity Enhancement

Detailed Description

This study was a 8 weeks, randomized, double-blind, placebo-controlled human trial. 40 subjects were randomly divided into Allium Cepa L. Peel Heated Water Extract or a placebo group. Immunity Enhancement profiles before and after the intervention.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
80
Inclusion Criteria
  • Age 19-75 years
  • Symptoms of upper respiratory infection at least once within past 12 months
Exclusion Criteria
  • Cardio-cerebrovascular, endocrine, immune, respiratory, musculoskeletal, inflammatory, hematologic, tumorigenic, gastrointestinal diseases, etc.
  • Vaccination within past 2 months
  • BMI < 18.5 kg/m2 or 35 kg/m2 ≤ BMI
  • Immunity enhancement agents within past one months
  • Allergic or hypersensitive to any of the ingredients in the test products
  • Antipsychotic drugs therapy within past 3 months
  • History of alcoholism or drug abuse
  • Participation in any other clinical trials within past 3 months
  • Pregnant or lactating women
  • Judged ineligible to participate in the trial by the principal investigator

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPlacebo4 capsules/day after meal(1,200 mg/day) for 8 weeks
Allium Cepa L. Peel Heated Water ExtractAllium Cepa L. Peel Heated Water Extract4 capsules/day after meal(1,200 mg/day) for 8 weeks
Primary Outcome Measures
NameTimeMethod
Changes of Natural killer(NK) cell activityAt week 0 and week 8

Changes of Natural killer(NK) cell activity will be assessed before and after the intervention.

PBMCs were isolated by density gradient separation, resuspended in phosphate-buffered saline, and determined using trypan blue solution. Natural killer(NK) cell activity was calculated from the results of nonradioactive cytotoxicity assay kits. Effector cells (PBMCs) were seeded in 96-well plates, with 50 ul of target cells (K562), incubated for 4 hours. cytotoxicity was calculated using the following formula: \[(experimental-effector spontaneous-target spontaneous)/(target maximum-target spontaneous)\]\*100.

Secondary Outcome Measures
NameTimeMethod
Changes of Cytokines(INF-gamma, Interleukin(IL)-2, IL-6, IL-12, Tumor Necrosis Factor(TNF)-alpha, and IL-1beta)At week 0 and week 8

Changes of Cytokines(INF-gamma, IL-2, IL-6, IL-12, TNF-alpha, and IL-1beta) will be assessed before and after the intervention.

the serum levels of cytokines, including INF-gamma, IL-2, IL-6, IL-12, TNF-alpha, and IL-1beta will be measured.

Changes of Wisconsin Upper Respiratory Symptom Survey-21At week 0 and week 4 and week 8

Changes of Wisconsin Upper Respiratory Symptom Survey-21 will be assessed before and after the intervention

Trial Locations

Locations (1)

Hanyang University

🇰🇷

Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath